- Agreement outlines an exclusive patent license granted to Wellgistics Health, giving the company sole access within its market segment to Datavault AI’s proprietary technologies.
- At the center of the initiative is PharmacyChain(TM), a platform designed to track and manage prescription fulfillment from manufacturer to patient while automating processes that are traditionally routed through PBMs.
- By granting exclusive, Datavault AI creates a stronger commercial incentive for adoption while also reinforcing the value of its intellectual property portfolio.
Prescription drug prices in the United States are among the highest in the world, driven in part by complex rebate structures controlled by pharmacy benefit managers (“PBMs”). Datavault AI (NASDAQ: DVLT), a technology company focused on AI-driven data monetization and digital asset infrastructure, is entering this landscape through an exclusive licensing agreement with Wellgistics Health Inc. The agreement positions the company’s technology at the center of a platform designed to streamline prescription distribution and reduce reliance on traditional intermediaries.
According to the company, the agreement outlines an exclusive patent license granted to Wellgistics Health, giving the company sole access within its market segment to Datavault AI’s proprietary technologies. This exclusivity is a defining feature of the agreement, as it prevents direct competitors from deploying the same intellectual property and establishes a differentiated position for Wellgistics within the pharmaceutical distribution ecosystem.
At the center of the initiative is PharmacyChain(TM), a platform designed to track and manage prescription fulfillment from manufacturer to patient while automating processes that are traditionally routed through PBMs. Rather than functioning as a conceptual blockchain layer, PharmacyChain is built on an existing operational foundation. Wellgistics already connects more than 6,500 independent pharmacies and over 200 pharmaceutical manufacturers, providing an established distribution network capable of supporting immediate deployment. The system is further supported by the EinsteinRx AI hub, which has already been completed and is designed to integrate analytics, automation and data-driven decision-making into prescription workflows.
The significance of this structure lies in its potential to reduce reliance on traditional intermediary models within pharmaceutical distribution. The companies describe PharmacyChain as a platform designed to track prescriptions across the supply chain while minimizing dependence on rebate-driven systems, positioning it as a more transparent and efficient alternative to conventional frameworks.
Leadership commentary from Wellgistics reinforces this objective. The company has emphasized that minimizing or eliminating PBM-related rebate structures is a central goal of its initiative, framing the PharmacyChain platform not simply as a technological upgrade but as a structural change to how prescription drugs are distributed and priced. Additional insight from Wellgistics president and interim CEO, Prashant Patel, RPh, also highlights the role of the company’s technology leadership, including expertise drawn from prior experience at OptumRx, one of the largest PBM organizations in the United States.
“By minimizing or eliminating PBM rebates for pharmacies and manufacturers while reducing administrative burden for payers, Wellgistics intends to disrupt and revolutionize the path through which prescription drugs are dispensed in the United States,” said Patel. “Further, given our CTO Srini Kalla’s background at OptumRX, we now possess all the ingredients necessary to develop new ways to reduce patients’ out-of-pocket costs by empowering them with the ability to monetize their data to manufacturers or other stakeholders within the healthcare system.”
From Datavault AI’s perspective, the agreement represents more than a single deployment. It is part of a broader strategy centered on licensing proprietary technology into regulated industries where data integrity, compliance and traceability are critical. The company’s platform is designed to convert real-world interactions and assets into structured, verifiable digital records that can support analytics, automation and monetization. In the context of healthcare, this capability extends to prescription tracking, identity verification and secure data exchange, all of which are essential in highly regulated environments.
The exclusivity of the Wellgistics license is particularly important within this strategy. By granting exclusive rights rather than entering into a nonexclusive partnership, Datavault AI creates a stronger commercial incentive for adoption while also reinforcing the value of its intellectual property portfolio. This approach mirrors a broader pattern in the company’s recent activity, where proprietary technologies are deployed through structured agreements that emphasize long-term monetization rather than one-time implementations.
Recent financial results provide additional context for the significance of this agreement. Datavault AI reported its first profitable quarter in its fiscal year 2025 results, with revenue reaching $39.1 million, representing a 1,362% increase year over year. The company has also indicated a trajectory toward substantially higher revenue in 2026, supported by a growing pipeline of licensing agreements and tokenization initiatives. Within that framework, the Wellgistics agreement stands out as an example of how the company is extending its platform into large, regulated markets with significant economic impact.
The collaboration also illustrates a broader convergence between healthcare infrastructure and advanced data systems. As the industry continues to evolve, stakeholders are increasingly focused on improving transparency, reducing inefficiencies and enabling more direct relationships between manufacturers, pharmacies and patients. By integrating Datavault AI’s technology into an existing network of pharmacies and manufacturers, the Wellgistics platform represents an attempt to operationalize those goals in a way that is both scalable and compliant.
While the long-term impact of PharmacyChain will depend on adoption and execution, the structure of the agreement provides a clear indication of intent. This is not a general technology partnership but an exclusive licensing arrangement tied to a defined platform with an existing network, a completed AI infrastructure layer and a specific target in addressing PBM-related inefficiencies. For Datavault AI, it represents another step in positioning its technology as an infrastructure layer within industries where data, compliance and monetization intersect.
For more information, visit www.DVLT.ai.
NOTE TO INVESTORS: The latest news and updates relating to DVLT are available in the company’s newsroom at https://ibn.fm/DVLT
About QualityStocks
QualityStocks (“QS”) is a specialized communications platform with a focus on private and public companies and the investment community. It is one of 75+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, QS is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, QS brings its clients unparalleled recognition and brand awareness. QS is where breaking news, insightful content and actionable information converge.
For more information, please visit https://www.QualityStocks.com
Please see full terms of use and disclaimers on the QualityStocks website applicable to all content provided by QS, wherever published or re-published: https://www.QualityStocks.com/Disclaimer
QualityStocks
Austin, Texas
www.QualityStocks.com
512.354.7000 Office
Editor@QualityStocks.com
QualityStocks is powered by IBN
